The three-zone site-rotation protocol described in Frid et al. 2016 and FIT injection recommendations, rationale, mapping, and lipohypertrophy prevention. Patient-education reference. Not medical advice.
Key points
- 01Zone 1. Abdomen. The abdominal zone, excluding a two-inch radius around the umbilicus, is described in Frid et al. 2016 as the primary site for subcutaneous administration. Absorption rates are most consistent at this site per the published pharmacokinetic literature for insulin and GLP-1 analogues.
- 02Zone 2. Anterolateral thigh. The anterior and lateral thigh is the secondary site described in FIT recommendations. The same literature notes a slightly slower absorption rate than the abdominal site for insulin preparations.
- 03Zone 3. Posterior upper arm. The posterior upper arm is the third described site. Self-administration is described as more technically demanding at this site; assisted administration is referenced in the nursing-education literature.
- 04Intra-zone spacing. Frid et al. 2016 and FIT recommendations describe a minimum spacing of approximately one centimetre between sequential injection points within a zone.
- 05Inter-zone rotation cadence. A weekly zone change, with intra-zone rotation between injections, is the convention described in the FIT injection-technique recommendations.
Frequently asked questions
What is the published rationale for site rotation?+
Frid et al. 2016 (Mayo Clinic Proceedings) and FIT injection-technique recommendations describe site rotation as the principal modifiable factor in preventing lipohypertrophy, which is associated with erratic drug absorption and reduced therapeutic consistency.
What is lipohypertrophy?+
Lipohypertrophy is thickening or nodular enlargement of subcutaneous tissue at repeatedly used injection sites. It is described in the published insulin-technique literature and in Frid et al. 2016 as a consequence of non-rotation of injection sites.
Do published absorption rates differ across the three zones?+
Yes. The published insulin pharmacokinetic literature describes the abdomen as the most consistent site, the thigh as slower, and the arm as intermediate. GLP-1 analogue package inserts (Ozempic, Wegovy, Mounjaro, Zepbound) describe their own absorption as not meaningfully dependent on site among the three documented zones.
What spacing between sites is described?+
FIT recommendations and Frid et al. 2016 describe a minimum of approximately one centimetre between sequential injection points within a zone to avoid re-use of the same skin microsite.
Is the buttock a documented injection site?+
The upper outer buttock is included as a fourth documented subcutaneous site in some nursing-reference texts, primarily for assisted administration. It is not typically included in self-administration guidance due to anatomical-access limitations.
How is lipohypertrophy detected?+
Frid et al. 2016 describes palpation of injection sites as the standard detection method, firm, thickened, or nodular areas distinct from surrounding tissue. Visual inspection alone is described as insufficient.
What does the guidance describe if lipohypertrophy is identified?+
The published guidance describes avoidance of the affected area until palpation returns to normal and adjustment of dose in consultation with the prescriber, as absorption from lipohypertrophic tissue is described as unreliable.
Sources
- Frid AH et al., 2016. New Insulin Delivery Recommendations, Mayo Clinic Proceedings
- Forum for Injection Technique (FIT). Injection Recommendations
- Blanco M et al., 2013. Prevalence and risk factors of lipohypertrophy in insulin-injecting patients, Diabetes & Metabolism
- Ozempic (semaglutide) Prescribing Information, injection site guidance
- CDC. Safe Injection Practices
